Avinger (AVGR)
(Delayed Data from NSDQ)
$1.29 USD
0.00 (0.00%)
Updated Aug 23, 2024 03:51 PM ET
After-Market: $1.26 -0.03 (-2.33%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.29 USD
0.00 (0.00%)
Updated Aug 23, 2024 03:51 PM ET
After-Market: $1.26 -0.03 (-2.33%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum B VGM
Zacks News
Avinger (AVGR) Launches Pantheris LV to Boost PAD Treatment
by Zacks Equity Research
Avinger (AVGR) fully launches Pantheris LV, the first image-guided atherectomy system for large vessels, thus enhancing peripheral artery disease treatment with advanced technology.
Avinger (AVGR) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Avinger (AVGR) delivered earnings and revenue surprises of -555.81% and 27.57%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Steris (STE) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 1% and 1.47%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging Avinger (AVGR) This Year?
by Zacks Equity Research
Here is how Avinger (AVGR) and Ayr Wellness Inc. (AYRWF) have performed compared to their sector so far this year.
Asensus Surgical (ASXC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Asensus Surgical (ASXC) delivered earnings and revenue surprises of -40% and 2.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
IQVIA Holdings (IQV) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
IQVIA (IQV) delivered earnings and revenue surprises of 2.83% and 1.22%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
TransMedics (TMDX) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of 800% and 16.24%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Avinger (AVGR) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Avinger (AVGR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are Medical Stocks Lagging Edwards Lifesciences (EW) This Year?
by Zacks Equity Research
Here is how Edwards Lifesciences (EW) and Avinger (AVGR) have performed compared to their sector so far this year.
Avinger (AVGR) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Avinger (AVGR) delivered earnings and revenue surprises of -2.46% and 24.29%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Intuitive Surgical, Inc. (ISRG) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of 3.55% and 1.37%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Avinger (AVGR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Avinger (AVGR) delivered earnings and revenue surprises of -20.41% and 11.26%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Codex DNA (DNAY) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Codex DNA (DNAY) delivered earnings and revenue surprises of 1.96% and 22.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Delcath Systems, Inc. (DCTH) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of -34.09% and 36.49%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
CVRx (CVRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CVRx (CVRX) delivered earnings and revenue surprises of 0% and 6.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Avinger (AVGR) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Avinger (AVGR) delivered earnings and revenue surprises of -92.56% and 0.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of -17.65% and 2%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Avinger (AVGR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Avinger (AVGR) delivered earnings and revenue surprises of 0% and 4.48%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 12.12% and 2.40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
LENSAR, Inc. (LNSR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
LENSAR, Inc. (LNSR) delivered earnings and revenue surprises of 31.67% and 31.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Natus Medical (NTUS) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Natus Medical (NTUS) delivered earnings and revenue surprises of 6.82% and 0.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Tactile Systems Technology (TCMD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of -566.67% and 6.03%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Avinger (AVGR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Avinger (AVGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avinger (AVGR) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Avinger (AVGR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Avinger (AVGR) Upgraded to Buy: Here's Why
by Zacks Equity Research
Avinger (AVGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).